- $14.53m
- $16.61m
- $2.29m
Brief: Femasys Announces FDA Approval Of Modular Pma Submission Approach For Fembloc
Femasys Inc reports results for the quarter ended June 30 - Earnings Summary
Femasys Inc expected to post a loss of $1.30 a share - Earnings Preview
Femasys Inc expected to post a loss of $1.30 a share - Earnings Preview
NASDAQ RESUMED AT 10:15 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:10 AM
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Femasys Expands Fertility Care Portfolio In Europe With CE Mark Approval For Femhsg™ Catheter
Femasys Q1 sales rise on FemBloc demand
Femasys 2025 sales jump on FemBloc demand
Brief: Femasys Enters Omnibus Amendment And Consent Agreement On March 19, 2026 - SEC Filing
Brief: Femasys Appoints Dr. Kenneth D. Eichenbaum To Board Of Directors
Brief: Femasys Granted 180-Day Extension By Nasdaq To Regain Compliance With Minimum Bid Price Requirement
Brief: Femasys Announces Partnership With Refuah Health Center To Expand First-Line Access To Femaseed® In Community-Based Care
Brief: Femasys Secures U.S. FDA Clearance For Next-Generation Femvue Diagnostic Device